Compare AU
Compare CURE vs. ETPMPM
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and ETPMPM. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | ETPMPM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 17 |
Median incremental investment | $619.50 | $851.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,475.04 | $1,753.78 |
Average age group | > 35 | > 35 |
Key Summary
CURE | ETPMPM | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | ETPMPM.AX was created on 2009-01-02 by Global X. The fund's investment portfolio concentrates primarily on broad market commodities. ETFS Physical Precious Metals Basket (ETPMPM.AX) is designed to offer investors a simple, cost-efficient and secure way to access physical gold, silver, platinum and palladium by providing a return equivalent to the movements in the spot price of the metals less the applicable management fee. |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | Global X Metal Securities Australia Limited (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.44 % |
Key Summary
CURE | ETPMPM | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P Biotechnology Select Industry | LBMA & LPPM Precious Metals Price PM - Benchmark TR Gross |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.44 % |
Price | $52.68 | $250.54 |
Size | $36.301 million | $59.300 million |
10Y return | N/A | 116.39 % |
Annual distribution/ dividend yield (5Y) | 4.24 % | - % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 30/01/2009 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | ETPMPM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 17 |
Median incremental investment | $619.50 | $851.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,475.04 | $1,753.78 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | ETPMPM | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | ETPMPM |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |